All In Biotech

Drug Trial Radar · NCT04411550

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

A (Randomised, Double-Blind, Intravenous Single-Dose, Parallel, Four-Arm) Phase I Clinical Study to Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta® (US, EU, and CN-Sourced) in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Jul 1, 2020

Primary completion

Jul 1, 2021

Study completion Jul 30, 2021

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Jun 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, intravenous single-dose, four-arm parallel study designed to compare the PK of HLX11 and US, EU, and CN-sourced Perjeta® in healthy Chinese adult male subjects, and to assess the safety, tolerability, and immunogenicity of these 4 drugs.

Conditions

  • Healthy Male Volunteers

Interventions

  • HLX11Drug

    healthy volunteers receive HLX11 (420mg) once

  • CN-Perjeta(Pertuzumab)Drug

    healthy volunteers receive CN-Perjeta (420mg) once

  • EU-Perjeta(Pertuzumab)Drug

    healthy volunteers receive EU-Perjeta (420mg) once

  • US-Perjeta(Pertuzumab)Drug

    healthy volunteers receive US-Perjeta (420mg) once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: from predose to 2352 hours (Day 99),13 timepoints
  2. AUC0~tTime frame: from predose to 2352 hours (Day 99),13 timepoints
  3. AUC0~infTime frame: from predose to 2352 hours (Day 99),13 timepoints

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.